Novo Holdings has completed its $16.5 billion acquisition of Catalent, the contract drug manufacturer said on Wednesday, days ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been ...

Novo Holdings, the controlling shareholder of Novo Nordisk, on Wednesday sealed its $16.5 billion deal for Catalent, as the ...

The all-cash deal has involved Novo Holdings acquiring Catalent for $16.5bn, including debt. It will then sell three of ...

After clearing all regulatory hurdles associated with its proposed buyout of CDMO Catalent, Novo Holdings is nearly ready to ...

Catalent, Inc. ("Catalent"), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences investment ...

The latest announcement is out from Catalent ( (CTLT) ).

Novo Holdings is on track to acquire Catalent, a global contract development and manufacturing organization, in a $16.5 ...

Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge ...

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...

Novo Holdings A/S completed the acquisition of Catalent, Inc. (CTLT), a global contract development and manufacturing ...